Navigation Links
Sosei Announces Filing of NDA for SOH-075 (NorLevo(R)) in Japan

TOKYO, September 30 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced the submission of the New Drug Application (NDA) for the emergency contraceptive pill SOH-075 (NorLevo(R)) to Ministry of Health, Labour and Welfare (MHLW) by Sosei Co. Ltd., its wholly owned Japanese subsidiary.

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse.

Sosei has acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA is supported by the data from Phase III study that was successfully completed in October 2008.

Editor's Notes:

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit

SOURCE Sosei Group Corporation

SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
2. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
3. Sosei Announces Outcome of Strategy Review
4. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
5. EPA announces research strategy to study nanomaterials
6. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
7. MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System
8. Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test
9. Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock
10. Spherix Incorporated Announces Annual Shareholders Meeting Date
11. Compendia Bioscience Announces the Release of Oncomine 4 Research Edition
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
(Date:11/24/2015)... ... 24, 2015 , ... Copper is an essential micronutrient that ... proteins, copper is also toxic to cells. With a $1.3 million award from ... conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), ...
(Date:11/24/2015)... ... 24, 2015 , ... This fall, global software solutions leader SAP and AdVenture ... develop and pitch their BIG ideas to improve health and wellness in their schools. ... to win the title of SAP's Teen Innovator, an all-expenses paid trip to Super ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/4/2015)... --> --> ... Transparency Market Research "Home Security Solutions Market - Global Industry ... 2022", the global home security solutions market is expected to reach ... market is estimated to expand at a CAGR of ... Rising security needs among customers at homes, the emergence ...
Breaking Biology News(10 mins):